07:00 , Apr 21, 2016 |  BC Innovations  |  Translation in Brief

Arginine and TH17 in lupus

GlaxoSmithKline plc 's (LSE:GSK; NYSE:GSK) launch of Benlysta belimumab for lupus in 2011 marked the first major advance for the disease since the introduction of corticosteroids and chemotherapeutic drugs decades ago, but there has been...
08:00 , Jan 26, 2015 |  BC Week In Review  |  Company News

Mars Symbioscience, Calithera Biosciences deal

Mars Symbioscience granted Calithera an exclusive, worldwide license to develop and commercialize the division’s portfolio of preclinical arginase inhibitors for use in human healthcare. Calithera said the program will help it submit an IND to...
07:00 , Jun 21, 2010 |  BC Week In Review  |  Company News

Arginetix, Immune Control deal

Arginetix and Immune Control merged to form Corridor Pharmaceuticals Inc. The newco will develop therapies for vascular diseases, initially focusing on pulmonary arterial hypertension (PAH). Corridor, which will be based in Baltimore, has designated Immune...
07:00 , Jun 21, 2010 |  BioCentury  |  Finance

Friendly persuasion

Arginetix Inc. and Immune Control Inc. agreed to merge last week in a union officiated by Quaker BioVentures, which saw an opportunity to combine a pair of early-stage portfolio companies in the same space. Gary...
08:00 , Dec 7, 2009 |  BioCentury  |  Emerging Company Profile

Arginetix: Another NO to PAH

Marketed therapeutics that target the endothelin, prostacyclin or nitric oxide pathways have improved the outcomes for patients with pulmonary arterial hypertension, yet mortality remains high. Arginetix Inc. believes its arginase inhibitors could complement marketed therapeutics...